Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

S. Z. Usmani; J. D. Cavenagh; A. R. Belch; C. Hulin; S. Basu; D. White; A. Nooka; A. Ervin-Haynes; W. Yiu; Y. Nagarwala; A. Berger; C. G. Pelligra; S. Guo; G. Binder; C. J. Gibson; T. Facon

doi:10.3111/13696998.2015.1115407

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

S. Z. Usmani, J. D. Cavenagh, A. R. Belch, C. Hulin, S. Basu, D. White, A. Nooka, A. Ervin-Haynes, W. Yiu, Y. Nagarwala, A. Berger, C. G. Pelligra, S. Guo, G. Binder, C. J. Gibson, T. Facon

Engineering

科研成果: 期刊稿件 › 文章 › 同行评审

22 引用（Scopus）

源语言	英语
页（从-至）	243-258
页数	16
期刊	Journal of Medical Economics
卷	19
期	3
DOI	https://doi.org/10.3111/13696998.2015.1115407
出版状态	已出版 - 3月 3 2016

!!!ASJC Scopus Subject Areas

卫生政策

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.3111/13696998.2015.1115407

其它文件与链接

引用此

Usmani, S. Z., Cavenagh, J. D., Belch, A. R., Hulin, C., Basu, S., White, D., Nooka, A., Ervin-Haynes, A., Yiu, W., Nagarwala, Y., Berger, A., Pelligra, C. G., Guo, S., Binder, G., Gibson, C. J., & Facon, T. (2016). Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. Journal of Medical Economics, 19(3), 243-258. https://doi.org/10.3111/13696998.2015.1115407

Usmani, SZ, Cavenagh, JD, Belch, AR, Hulin, C, Basu, S, White, D, Nooka, A, Ervin-Haynes, A, Yiu, W, Nagarwala, Y, Berger, A, Pelligra, CG, Guo, S, Binder, G, Gibson, CJ & Facon, T 2016, 'Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma', Journal of Medical Economics, 卷 19, 号码 3, 页码 243-258. https://doi.org/10.3111/13696998.2015.1115407

@article{370c080b9c934b6f884fe0cddbf493c5,

title = "Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma",

keywords = "Bortezomib, Cost-benefit analysis, Cost-effectiveness, Drug therapy, Lenalidomide, Multiple myeloma",

author = "Usmani, {S. Z.} and Cavenagh, {J. D.} and Belch, {A. R.} and C. Hulin and S. Basu and D. White and A. Nooka and A. Ervin-Haynes and W. Yiu and Y. Nagarwala and A. Berger and Pelligra, {C. G.} and S. Guo and G. Binder and Gibson, {C. J.} and T. Facon",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor and Francis.",

year = "2016",

month = mar,

day = "3",

doi = "10.3111/13696998.2015.1115407",

language = "English",

volume = "19",

pages = "243--258",

journal = "Journal of Medical Economics",

issn = "1369-6998",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

AU - Usmani, S. Z.

AU - Cavenagh, J. D.

AU - Belch, A. R.

AU - Hulin, C.

AU - Basu, S.

AU - White, D.

AU - Nooka, A.

AU - Ervin-Haynes, A.

AU - Yiu, W.

AU - Nagarwala, Y.

AU - Berger, A.

AU - Pelligra, C. G.

AU - Guo, S.

AU - Binder, G.

AU - Gibson, C. J.

AU - Facon, T.

PY - 2016/3/3

Y1 - 2016/3/3

KW - Bortezomib

KW - Cost-benefit analysis

KW - Cost-effectiveness

KW - Drug therapy

KW - Lenalidomide

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84959140493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959140493&partnerID=8YFLogxK

U2 - 10.3111/13696998.2015.1115407

DO - 10.3111/13696998.2015.1115407

M3 - Article

C2 - 26517601

AN - SCOPUS:84959140493

SN - 1369-6998

VL - 19

SP - 243

EP - 258

JO - Journal of Medical Economics

JF - Journal of Medical Economics

IS - 3

ER -

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此